CRISPR company Intellia prices IPO

May 6, 2016 News BioVox

Gene editing company Intellia Therapeutics Inc. (NASDAQ:NTLA) raised $108 million on Thursday through the sale of 6 million shares at $18 in an IPO underwritten by Credit Suisse, Jefferies, Leerink and Wedbush PacGrow. In a regulatory filing earlier Thursday, Intellia said it hoped to sell 5 million shares at $16-$18.

Intellia is one of a handful of companies developing products using CRISPR-Cas9 (CRISPR-associated protein 9) genome editing technology. The first to go public, Editas Medicine Inc. (NASDAQ:EDIT), closed at $31.99 on Thursday, up 100% from its Feb. 2 IPO price of $16.

Intellia expects its shares to begin trading on Friday.

Adapted from BioCentury.


Avatar photo
BioVox

With a local focus and global reach, BioVox shares insights into the Belgian life sciences ecosystem with an ever-growing global community. BioVox is a non-profit project: we are able to provide our community with free, quality content because of the generous support of Turnstone Communications and its clients. Our articles bring you hidden opportunities and exclusive insights into the latest research and industry trends!

All posts